Clinical Trials Arena on MSN
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...
Gilead (GILD) stock gains as the company's new single-tablet HIV regimen is proven as effective as multi-tablet therapies in ...
Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.
TipRanks on MSN
Gilead announces ARTISTRY-1 trial meets primary endpoint
Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with ...
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, ...
A $16 million planned gift from a longtime University of Maryland faculty member will empower researchers and students in the Department of Cell Biology and Molecular Genetics to conduct research on ...
This article introduces the field of bioinformatics and its importance as a cornerstone of biological research, as well as ...
A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...
Q3 2025 Earnings Call November 10, 2025 8:30 AM ESTCompany ParticipantsKate Rausch - Head of Investor RelationsPaul Bolno ...
-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback